← All trials
NCT03893448
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2019
- Primary completion
- Dec 22, 2020
- Completion date
- May 20, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 1720
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- hepatitis a vaccine, inactivated
- live attenuated varicella vaccine
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- 15-valent pneumococcal conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.